ESR1 and cancer: Whilst adjuvant tamoxifen significantly reduces both cancer recurrence and cancer related mortality, recurrence amongst ER+ patients whilst still on tamoxifen therapy lies in the region of 25% at 10 years, with around 60% of these recurrences occurring within the first 5 years [3].